Vestal Point Capital LP Increases Holdings in Savara Inc (NASDAQ:SVRA)

Vestal Point Capital LP boosted its position in shares of Savara Inc (NASDAQ:SVRA) by 24.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,090,000 shares of the company’s stock after purchasing an additional 1,600,000 shares during the quarter. Savara comprises about 2.6% of Vestal Point Capital LP’s portfolio, making the stock its 14th biggest position. Vestal Point Capital LP owned 4.91% of Savara worth $34,302,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. CANADA LIFE ASSURANCE Co purchased a new stake in Savara in the first quarter worth about $35,000. Choreo LLC purchased a new stake in shares of Savara in the 2nd quarter worth approximately $59,000. DRW Securities LLC bought a new position in shares of Savara during the second quarter valued at approximately $62,000. Principal Financial Group Inc. increased its holdings in Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after buying an additional 6,973 shares during the period. Finally, Profund Advisors LLC bought a new position in Savara in the second quarter worth approximately $105,000. 87.93% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

SVRA has been the topic of several recent research reports. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. HC Wainwright decreased their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Savara has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Insider Activity

In other news, Director Joseph S. Mccracken bought 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of $2.95 per share, with a total value of $59,000.00. Following the completion of the acquisition, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.13% of the company’s stock.

Savara Stock Performance

Shares of SVRA stock opened at $3.47 on Friday. Savara Inc has a fifty-two week low of $2.82 and a fifty-two week high of $5.70. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The stock’s 50-day simple moving average is $3.68 and its 200-day simple moving average is $4.09.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). As a group, sell-side analysts forecast that Savara Inc will post -0.45 EPS for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.